Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Sell
19
BTAI Quote, Financials, Valuation and Earnings
Last price:
$1.80
Seasonality move
:
7.96%
Day range:
$1.88 - $2.02
52-week range:
$1.72 - $49.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.23x
P/B ratio:
--
Volume:
97.5K
Avg. volume:
9.2M
1-year change:
-95.29%
Market cap:
$10.9M
Revenue:
$2.3M
EPS (TTM):
-$2.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics
|
$350K | -$3.04 | -39.86% | -78.16% | $48.00 |
|
CMRX
Chimerix
|
-- | -$0.27 | 7665% | -8% | $8.54 |
|
IGMS
IGM Biosciences
|
$4.3M | -$0.45 | 401.41% | -42.68% | $2.13 |
|
OMER
Omeros
|
$400K | -$0.60 | -- | -373.33% | $36.00 |
|
SCPH
scPharmaceuticals
|
$11.6M | -$0.29 | 90.57% | -23.15% | $15.17 |
|
ZVSA
ZyVersa Therapeutics
|
-- | -$2.73 | -- | -91.71% | $70.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics
|
$1.99 | $48.00 | $10.9M | -- | $0.00 | 0% | 2.23x |
|
CMRX
Chimerix
|
$8.52 | $8.54 | $799.2M | -- | $0.00 | 0% | -- |
|
IGMS
IGM Biosciences
|
$1.23 | $2.13 | $73.5M | -- | $0.00 | 0% | 27.78x |
|
OMER
Omeros
|
$8.01 | $36.00 | $464.2M | -- | $0.00 | 0% | -- |
|
SCPH
scPharmaceuticals
|
$2.50 | $15.17 | $125.7M | -- | $0.00 | 0% | 3.06x |
|
ZVSA
ZyVersa Therapeutics
|
$0.59 | $70.00 | $1.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics
|
555.33% | -2.069 | 403.22% | 1.58x |
|
CMRX
Chimerix
|
-- | -9.573 | -- | 5.55x |
|
IGMS
IGM Biosciences
|
-- | -0.964 | -- | 4.88x |
|
OMER
Omeros
|
-- | 7.483 | -- | -- |
|
SCPH
scPharmaceuticals
|
79.4% | 0.692 | 28.96% | 5.87x |
|
ZVSA
ZyVersa Therapeutics
|
-- | 1.150 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BTAI
BioXcel Therapeutics
|
-$956K | -$13.7M | -197.92% | -- | -4607.48% | -$16.3M |
|
CMRX
Chimerix
|
-- | -$24.6M | -56.64% | -56.65% | -43073.68% | -$19.4M |
|
IGMS
IGM Biosciences
|
-- | -$39M | -159.45% | -159.45% | -9461.17% | -$35.7M |
|
OMER
Omeros
|
-- | -$35.4M | -- | -- | -- | -$32.1M |
|
SCPH
scPharmaceuticals
|
$8.2M | -$16.3M | -126.82% | -370.01% | -142.88% | -$15.2M |
|
ZVSA
ZyVersa Therapeutics
|
-- | -$2.3M | -- | -- | -- | -$644.4K |
BioXcel Therapeutics vs. Competitors
-
Which has Higher Returns BTAI or CMRX?
Chimerix has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of -40270.18%. BioXcel Therapeutics's return on equity of -- beat Chimerix's return on equity of -56.65%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics-446.73% -$0.32 $18.8M CMRXChimerix-- -$0.25 $121.7M -
What do Analysts Say About BTAI or CMRX?
BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2312.06%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could grow by 0.24%. Given that BioXcel Therapeutics has higher upside potential than Chimerix, analysts believe BioXcel Therapeutics is more attractive than Chimerix.
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics1 1 0 CMRXChimerix1 3 0 -
Is BTAI or CMRX More Risky?
BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.
-
Which is a Better Dividend Stock BTAI or CMRX?
BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or CMRX?
BioXcel Therapeutics quarterly revenues are $214K, which are larger than Chimerix quarterly revenues of $57K. BioXcel Therapeutics's net income of -$13.7M is higher than Chimerix's net income of -$23M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.23x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics2.23x -- $214K -$13.7M CMRXChimerix-- -- $57K -$23M
-
Which has Higher Returns BTAI or IGMS?
IGM Biosciences has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of -8894.9%. BioXcel Therapeutics's return on equity of -- beat IGM Biosciences's return on equity of -159.45%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics-446.73% -$0.32 $18.8M IGMSIGM Biosciences-- -$0.61 $48.2M -
What do Analysts Say About BTAI or IGMS?
BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2312.06%. On the other hand IGM Biosciences has an analysts' consensus of $2.13 which suggests that it could grow by 72.76%. Given that BioXcel Therapeutics has higher upside potential than IGM Biosciences, analysts believe BioXcel Therapeutics is more attractive than IGM Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics1 1 0 IGMSIGM Biosciences0 6 1 -
Is BTAI or IGMS More Risky?
BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.126%.
-
Which is a Better Dividend Stock BTAI or IGMS?
BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or IGMS?
BioXcel Therapeutics quarterly revenues are $214K, which are smaller than IGM Biosciences quarterly revenues of $412K. BioXcel Therapeutics's net income of -$13.7M is higher than IGM Biosciences's net income of -$36.6M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.23x versus 27.78x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics2.23x -- $214K -$13.7M IGMSIGM Biosciences27.78x -- $412K -$36.6M
-
Which has Higher Returns BTAI or OMER?
Omeros has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat Omeros's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics-446.73% -$0.32 $18.8M OMEROmeros-- -$0.56 -- -
What do Analysts Say About BTAI or OMER?
BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2312.06%. On the other hand Omeros has an analysts' consensus of $36.00 which suggests that it could grow by 349.44%. Given that BioXcel Therapeutics has higher upside potential than Omeros, analysts believe BioXcel Therapeutics is more attractive than Omeros.
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics1 1 0 OMEROmeros1 2 0 -
Is BTAI or OMER More Risky?
BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison Omeros has a beta of 2.352, suggesting its more volatile than the S&P 500 by 135.194%.
-
Which is a Better Dividend Stock BTAI or OMER?
BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or OMER?
BioXcel Therapeutics quarterly revenues are $214K, which are larger than Omeros quarterly revenues of --. BioXcel Therapeutics's net income of -$13.7M is higher than Omeros's net income of -$32.2M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.23x versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics2.23x -- $214K -$13.7M OMEROmeros-- -- -- -$32.2M
-
Which has Higher Returns BTAI or SCPH?
scPharmaceuticals has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of -155.1%. BioXcel Therapeutics's return on equity of -- beat scPharmaceuticals's return on equity of -370.01%.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics-446.73% -$0.32 $18.8M SCPHscPharmaceuticals67.37% -$0.35 $64.7M -
What do Analysts Say About BTAI or SCPH?
BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2312.06%. On the other hand scPharmaceuticals has an analysts' consensus of $15.17 which suggests that it could grow by 506.67%. Given that BioXcel Therapeutics has higher upside potential than scPharmaceuticals, analysts believe BioXcel Therapeutics is more attractive than scPharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics1 1 0 SCPHscPharmaceuticals4 0 0 -
Is BTAI or SCPH More Risky?
BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison scPharmaceuticals has a beta of 0.380, suggesting its less volatile than the S&P 500 by 61.958%.
-
Which is a Better Dividend Stock BTAI or SCPH?
BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. scPharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. scPharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or SCPH?
BioXcel Therapeutics quarterly revenues are $214K, which are smaller than scPharmaceuticals quarterly revenues of $12.2M. BioXcel Therapeutics's net income of -$13.7M is higher than scPharmaceuticals's net income of -$18.8M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while scPharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.23x versus 3.06x for scPharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics2.23x -- $214K -$13.7M SCPHscPharmaceuticals3.06x -- $12.2M -$18.8M
-
Which has Higher Returns BTAI or ZVSA?
ZyVersa Therapeutics has a net margin of -6378.51% compared to BioXcel Therapeutics's net margin of --. BioXcel Therapeutics's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BTAIBioXcel Therapeutics-446.73% -$0.32 $18.8M ZVSAZyVersa Therapeutics-- -$2.43 -- -
What do Analysts Say About BTAI or ZVSA?
BioXcel Therapeutics has a consensus price target of $48.00, signalling upside risk potential of 2312.06%. On the other hand ZyVersa Therapeutics has an analysts' consensus of $70.00 which suggests that it could grow by 3305.42%. Given that ZyVersa Therapeutics has higher upside potential than BioXcel Therapeutics, analysts believe ZyVersa Therapeutics is more attractive than BioXcel Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings BTAIBioXcel Therapeutics1 1 0 ZVSAZyVersa Therapeutics1 0 0 -
Is BTAI or ZVSA More Risky?
BioXcel Therapeutics has a beta of 0.640, which suggesting that the stock is 36.034% less volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BTAI or ZVSA?
BioXcel Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXcel Therapeutics pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BTAI or ZVSA?
BioXcel Therapeutics quarterly revenues are $214K, which are larger than ZyVersa Therapeutics quarterly revenues of --. BioXcel Therapeutics's net income of -$13.7M is lower than ZyVersa Therapeutics's net income of -$2.4M. Notably, BioXcel Therapeutics's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXcel Therapeutics is 2.23x versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BTAIBioXcel Therapeutics2.23x -- $214K -$13.7M ZVSAZyVersa Therapeutics-- -- -- -$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
